期刊
MOLECULAR CARCINOGENESIS
卷 43, 期 4, 页码 198-206出版社
WILEY
DOI: 10.1002/mc.20111
关键词
troglitazone; rosiglitazone; chemoprevention; skin carcinogenesis
资金
- NCI NIH HHS [CA16672, CN65110-72] Funding Source: Medline
- NIEHS NIH HHS [ES07784] Funding Source: Medline
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a ligand activated transcription factor. There have been suggestions that PPAR gamma ligands may have utility in preventing tumor development in rodent mammary glands and colon. The recent finding that mice lacking one allele of the PPAR gamma gene were significantly more susceptible to 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis compared to wild-type mice highlights mouse skin as another potential organ in which PPAR-gamma ligands may be effective as chemopreventive agents. In this study, we assessed the effect of two PPAR gamma ligands (rosiglitazone and troglitazone) on UV and DMBA/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis, two of the most commonly used mouse skin carcinogenesis models. Unexpectedly, neither rosiglitazone (dietary 200 ppm) nor troglitazone (topical 100 mu g) significantly inhibited UV-induced skin tumor development in SKH-1 hairless mice. Likewise, dietary rosiglitazone did not statistically significantly inhibit DMBA/TPA-induced skin tumor development. Interestingly, dietary troglitazone significantly inhibited basal level keratinocyte proliferation as shown by 5-bromo-2'-deoxyuridine (BrdU) labeling, but it had no effect on TPA-induced epidermal cell proliferation. Northern blot analysis showed that PPAR gamma expression was extremely low in normal mouse epidermis and was virtually undetectable in skin tumors. Collectively, our data suggest that PPAR gamma ligands may not be useful in the prevention of chemically or UV-induced skin tumors. (c) 2005 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据